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and probably CREB (Yasuda et al., 2008).
Pre-BCR signaling may also downregu-
late transcription factors that enforce qui-
escence. TIS21, a member of the BTG
(also known as TOB) family of transcrip-
tion factors, appears to keep thymocytes
quiescent prior to b-selection, and its
expression is downregulated by pre-TCR
signaling (Konrad and Zuniga-Pflucker,
2005).
ERK may also promote B cell develop-
ment by phosphorylating c-Myc, Bim,
and cyclin D3. This modification stabilizes
c-Myc and induces degradation of the
pro-apoptotic Bim protein. Cyclin D3 is
required for pre-B cell proliferation (Coo-
per et al., 2006). IL-7 induces its expres-
sion, but pre-BCR signaling via phospha-
tidylinositol 3-kinase protects cyclin D3
from degradation. The role of ERK in cy-
clin D3 stabilization has not been tested,
but phosphatidylinositol 3-kinase has
been implicated in BCR-induced ERK
activation.
Yasuda et al. (2008) have provided im-
portant new molecular insights into how
the pre-BCR drives the pro-B to pre-BII
transition. Together with the identification
of genes that may regulate the pre-BII to
immature B cell transition (Schuh et al.,
2008), this forms the basis for a fuller
understanding of critical steps in B cell
development.
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Dendritic cells are a heterogeneous group of antigen presenting cells. In this issue of Immunity, Esashi et al.
(2008) demonstrate how cytokine-receptor-regulated downstream transcription factors direct dendritic cell
subpopulation differentiation from hematopoietic progenitor cells.Dendritic cells (DCs) are central regulators
in both priming of innate and adaptive
immune responses and in maintaining
self-tolerance. Multiple DC subsets have
been identified on the basis of their phe-
notype, location, maturation state, and
functional properties (Shortman and
Naik, 2007). In steady-state mouse lym-
phoid tissues, DCs can be classified in
at least two main populations, ‘‘plasma-
cytoid’’ DCs (pDCs) and conventional
DCs (cDCs), which can further be subdi-
vided into three subsets on the basis
of surface-molecule expression. Most
steady-state lymphoid tissue DCs have
a half-life of only few days and do not490 Immunity 28, April 2008 ª2008 Elsevierself-renew, and therefore they continu-
ously need to be replaced by bone-
marrow hematopoietic stem cells via
respective developmental intermediates,
i.e., hematopoietic progenitor cells. How
is DC differentiation and maintenance
from hematopoietic stem cells guided in
steady state and disease, what are the
developmental intermediates, and which
environmental factors are critical? Fur-
thermore, how do these environmental
factors translate molecularly in progeni-
tors to shape the transcriptional program,
thereby leading to proliferation, differenti-
ation, correct location, and finally function
of DCs? Substantial knowledge on allInc.these questions has been acquired over
the last years.
Granulocyte-macrophage colony stim-
ulating factor (GM-CSF) with or without in-
terleukin-4 was first demonstrated to lead
to in vitro DC differentiation from whole
bone-marrow cells or monocytes in both
mice and man, and this efficient method
of DC generation is now frequently used
in both laboratory research and clinical
applications. However, only Flt3-ligand
stimulation of bone-marrow progenitors
induces generation of both pDCs and
cDCs, resembling DC populations in
lymphoid organs, whereas addition of
GM-CSF (with orwithout TNFa) to cultures
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Previewsblocks pDC development (Gilliet et al.,
2002), a finding later confirmed in human
hematopoietic progenitor cells. Further-
more, macrophage-colony stimulating
factor (M-CSF) was most recently shown
to enhance both in vitro pDC and cDC
differentiation from mouse progenitor
cells, especially when combined with
Flt3-ligand stimulation (Fancke et al.,
2008;Onai et al., 2007).Micewith targeted
deletions of the genes encoding GM-CSF,
M-CSF, or Flt3-ligand and mice with
the respective receptor deletions have
been generated. Both GM-CSF and M-
CSF and respective receptor null mice
have normal or slightly reduced lym-
phoid-tissue DC numbers, with only epi-
dermal dendritic cells (Langerhans cells)
being not produced from M-CSFR-defi-
cient cells, and are thus dispensable for
steady-state lymphoid-organ DC genera-
tion (Shortman and Naik, 2007). In con-
trast, Flt3-ligand-deficient mice have
approximately one-tenth the numbers of
lymphoid-tissue pDCs and cDCs, defining
Flt3-ligand as a nonredundant cytokine for
in vivo steady-state lymphoid-organ DC
maintenance (McKenna et al., 2000).
Interestingly, bone-marrow dendritic cell
progenitors as well as steady-state lym-
phoid-organ dendritic cells express the re-
spective receptors for all three cytokines
(Flt3 ligand, GM-CSF, and M-CSF) and
are able to respond to each of them (Onai
et al., 2007; Shortman and Naik, 2007).
A recent article in Immunity (Laouar
et al., 2003) and the work by Esashi
et al. (2008) in this issue provide under-
standing of how Flt3-ligand and GM-
CSF-mediated signals are integrated at
the point of transcription to guide DC
subtype differentiation from dendritic cell
progenitors via differential activation of
signal transducer and activator of tran-
scription (STAT) factors, whereas M-CSF
downstream signaling in DC development
remains to be determined. Laouar et al.
(2003) demonstrates that hematopoie-
sis-confined STAT3 deficiency leads to
reduction of steady-state DCs to one-
tenth the numbers of wild-type mice
(resembling the phenotype of Flt3-
ligand-deficient mice). This DC deficiency
is not overcome by either Flt3-ligand
injection or in vivo lipopolysaccharide
induced general inflammation. Further-
more, they show that STAT3 is activated
downstream of Flt3, thus demonstrating
that STAT3 is required for Flt3-ligand-Figure 1. GM-CSF and Flt3 Receptor Downstream Signaling in DC Development
Green and red lines indicate supportive and inhibitory action, and bold and dotted lines refer to direct and
indirect interactions, respectively. GM-CSFR activates STAT5 that directly inhibits Irf8 transcription, thus
leading to suppression of pDC differentiation (Esashi et al., 2008).dependent DC differentiation, a process
probably executed via transcriptional ac-
tivation of DC differentiation supporting
factors such as e.g., Spi-B, PU.1, and
IRF-7 (Onai et al., 2006; Zenke and Hiero-
nymus, 2006). In contrast, GM-CSF-
driven in vitro cDC development is not
inhibited by STAT3 deficiency (Laouar
et al., 2003). Further weight to the idea
that STAT3 is an important DC differentia-
tion factor is given by the finding that
enforced expression and activation of
STAT3 in hematopoietic progenitors
normally lacking DC potential instructs
differentiation into both pDCs and cDCs
(Onai et al., 2006). By using STAT3- and
STAT5-deficient hematopoietic cells in
in vitro and in vivo assays, Esashi et al.
(2008) now elegantly provide the explana-
tion of why GM-CSF as a single cytokine
or as addition to Flt3-ligand cultures
inhibits pDC and favors cDC development
(Gilliet et al., 2002): GM-CSF activates
STAT5, which in turn directly inhibits tran-
scription of IRF-8 (also called interferon
consensus binding protein [ICSBP]), a
protein previously demonstrated to be
essential for the development of pDCs
and CD8a+CD4 cDCs in vivo (Schiavoni
et al., 2002). Also, they demonstrate that
GM-CSF-mediated STAT5 activation, di-
rectly or indirectly, leads to inhibition of
the transcription factors Spi-B and IRF-
7, the cytokine receptor Flt3, and the
pathogen-recognition receptor TLR9, allImmshown to be important in pDC differentia-
tion and function (Shortman and Naik,
2007; Zenke and Hieronymus, 2006).
However, besides activation of STAT5,
GM-CSF also leads to activation of
STAT3 and expression of IRF-4, a tran-
scription factor important in cDC (espe-
cially CD8aCD4+) development (Esashi
et al., 2008; Shortman and Naik, 2007;
Zenke and Hieronymus, 2006). Thus,
a picture of STAT-regulated DC devel-
opment from hematopoietic progenitors
under the influence of either Flt3-ligand
or GM-CSF emerges: In Flt3-signaling-
mediated steady-state pDC and cDC de-
velopment, STAT3 activation is a nonre-
dundant requirement, whereas STAT5 is
dispensable; in GM-CSF-signaling-medi-
ated cDC development, STAT3 is dis-
pensable and activated STAT5 sup-
presses pDC development. However, in
the absence of STAT5, pDCs develop
in GM-CSF stimulated cultures, possibly
via GM-CSF-mediated STAT3 activation.
Interestingly, GM-CSF-stimulated STAT5-
deficient progenitors seem to produce
fewer cDCs; thus it is possible that
beyond suppression of pDC develop-
ment, STAT5 is also directly involved in
GM-CSF-mediated cDC development,
an issue that needs further clarification.
Furthermore, STAT3 overexpression and
activation, i.e., strong Flt3-downstream
signaling, seems to favor pDC over cDC
development (Onai et al., 2006). Dataunity 28, April 2008 ª2008 Elsevier Inc. 491
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Previewsfrom the abovementioned studies (Laouar
et al., 2003; Onai et al., 2006; Esashi et al.,
2008) are summarized in Figure 1.
What are the implications of differential
cytokine- and downstream STAT-regu-
lated DC development in vivo, and specif-
ically, in which situation is cDC develop-
ment at cost of pDC development
biologically beneficial? Whereas respec-
tive receptor expression is relatively re-
stricted to hematopoietic cells, Flt3 ligand
is broadly expressed in steady state by
multiple tissue stromal cells and by acti-
vated T cells; GM-CSF is produced by
some stromal cells as well as activated T
and NK cells, and macrophages; and
main sources of M-CSF include stromal
cells and endothelial cells, as well as
macrophages. All three cytokine amounts
increase in serum upon systemic inflam-
mation, for example in some infections
or autoimmune diseases, and upon
hematopoietic challenge, such as irradia-Cancer Immunosu
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The idea of cancer immunosurveillan
et al. (2008) present the first genetic
ciated receptor.
Since their discovery, a large number of
studies have demonstrated natural killer
(NK) cell-mediated lysis of different types
of tumor cells in vitro, as well as NK cell-
dependent elimination of many tumors
in vivo. For a long time, it was unknown
how NK cells recognized tumor cells, as
well as other aberrant cells. Over the last
15 years, however, a large number of
germline-encoded NK cell-activation and
-inhibitory receptors have been discov-
ered (Lanier, 2005). NK cell-inhibitory re-
ceptors, most of which recognize major
histocompatibility complex (MHC) class I
molecules, were the first NK cell receptors
to be identified. After the discovery of
these, a large number of different NK
492 Immunity 28, April 2008 ª2008 Elseviertion-induced cytopenia. Less is known,
however, on local cytokine amounts in
a dynamically changing environment.
Thus, in contrast to controlled in vitro
situations in which cytokines effects are
studied under exclusive and probably sat-
urating conditions, DC progenitors in vivo
are exposed to subtle gradient changes
that, once a threshold is reached, will
probably shape their differentiation fate.
The study published here provides an
exciting step forward in envisioning the
in vivo situation and, as also suggested
by the authors, might guide in develop-
ing therapeutic approaches, for example
to diseases in which pDC excess is of
pathogenetic relevance.
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